Condition 1: Idiopathic infertility. Condition 2: Erectile Dysfunction. Male infertility Failure of genital response
Conditions
Interventions
Intervention 1: Intervention group: Sildenafil citrate 50 mg tablet, one dose, made in Iran. Intervention 2: Control group: Placebo 50 mg tablet, one dose, made in Iran.
Treatment - Drugs
Placebo
Intervention group: Sildenafil citrate 50 mg tablet, one dose, made in Iran
Control group: Placebo 50 mg tablet, one dose, made in Iran
Sponsors
Urology Research Centre, Guilan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
25 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age range 25 to 40 years; normal erectile function; no history of acute febrile disease; no history of related drug use within 3 months before study Exclusion criteria: Any factor that causes the testicles to get in contact with high temperatures includes long hot bath, sauna, bakery and other high-risk jobs; people with a history of seasonal allergies and sensitivities; consumption of alcohol, cocaine and certain medications, such as cimetidine, spironolactone, erythromycin, corticosteroids and methylxanthines such as theophylline, pentoxifylline and aminophylline and especially nitrates; history of testicular trauma or surgery; cardiovascular disease or high blood pressure and/or diabetes mellitus; consumption of hypertension drugs; consumption of drugs for the treatment of infertility
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ejaculation Volume. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Sperm Concentration. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Sperm Count. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Sperm Motility. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Sperm Vitality. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Sperm Morphology. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sperm forward progression. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Appearance of Semen. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Sperm ph. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Semen viscosity. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis.;Liquefaction. Timepoint: Before intervention and 3 days later, one hour after taking the drug or placebo and again a week later with an interval of one hour after drug or placebo (in general, it will be measured 3 times). Method of measurement: Semen analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Soheil Kiyanfar
Urology Research Center, Guilan University of Medical Sciences
Outcome results
None listed